Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01
Rhea-AI Summary
Evaxion (NASDAQ: EVAX) completed the one-year extension of its phase 2 trial of personalized cancer vaccine EVX-01, with the last patient visit on April 7, 2026.
First-two-year results showed a 75% Objective Response Rate (12/16), four complete responses, 92% still responding at two years, and high immunogenicity (81% neoantigen response). Three-year efficacy data are expected in the second half of 2026.
Positive
- Objective Response Rate 75% (12 of 16 patients)
- Four complete responses among 16 patients
- 92% durable response at two-year follow-up
- 81% neoantigen immunogenicity induced by EVX-01
- Tumor reduction in 15 of 16 patients
Negative
- Small trial cohort: 16 patients limits broad generalizability
- Key three-year efficacy data pending in H2 2026
News Market Reaction – EVAX
In the Apr 7 session, EVAX gained 2.01%, reflecting a moderate positive market reaction. Argus tracked a trough of -6.8% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 25 | EVX-01 trial extension | Positive | -11.1% | Extended EVX-01 phase 2 to three years for more outcome data. |
| Jan 15 | EVX-01 dosing complete | Positive | -12.9% | Completed dosing of all 16 patients in EVX-01 phase 2 trial. |
| Nov 12 | EVX-V1 preclinical data | Positive | -1.6% | Reported positive preclinical data for CMV vaccine EVX-V1. |
| Sep 09 | EVX-01 efficacy update | Positive | -5.8% | Announced 69% Overall Response Rate in EVX-01 phase 2 trial. |
| Apr 17 | EVX-01 dosing milestone | Positive | +1.7% | First patient completed dosing in EVX-01 phase 2 trial. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical trial headlines for Evaxion have often coincided with negative next-day moves despite generally positive data updates.
Recent history for Evaxion’s clinical programs shows a steady EVX-01 progression from first patient dosing in April 2024 to interim efficacy readouts and subsequent trial extension. Earlier EVX-01 updates with 69% Overall/Objective Response Rates and strong immunogenicity were followed by negative price reactions. Today’s completion of the one-year phase 2 extension and confirmation of robust two-year data fit this pattern of positive clinical signals not always translating into supportive short-term trading.
Key Terms
objective response rate medical
anti-pd-1 therapy medical
pembrolizumab medical
monotherapy medical
neoantigens medical
t-cell responses medical
advanced melanoma medical
immune response medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Trial extension completed as planned with three-year clinical efficacy data expected to be presented in the second half of 2026
- The trial has already yielded encouraging one- and two-year data including a
75% Objective Response Rate
COPENHAGEN, Denmark, April 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has successfully completed the one-year extension of its phase 2 trial with personalized cancer vaccine EVX-01 with the last patient having now had last physician visit. Patients in the trial will continue to be monitored and data prepared for expected presentation in the second half of 2026.
Designed with AI-Immunology™, EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer). In the first two years of the phase 2 trial, patients were treated with EVX-01 in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, Keytruda® (pembrolizumab).
In the third year, patients received EVX-01 as monotherapy, allowing an evaluation of the vaccine’s effect both as stand-alone and combination treatment. Further, the three-year data may provide additional insights into potential enhanced treatment effects and durability of induced immune response.
“We are pleased to have carried through the extension of the trial as planned and are looking forward to collecting, analysing and presenting the data. EVX-01 already has a very strong data package demonstrating the unique capabilities of AI-Immunology™ in cancer vaccine design. We hope to further enhance the data package with the three-year results,” says Birgitte Rønø, CSO of Evaxion.
Encouraging data
Data from the first two years of the trial demonstrated an Objective Response Rate of
In the trial, EVX-01 induced an immune response in all patients, with
Data also confirmed EVX-01 to be a well-tolerated treatment.
Contact information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai
About Evaxion
Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.
With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development
We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.
For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
